Cargando…

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies

The members of the Poly(ADP‐ribose) polymerase (PARP) superfamily are involved in several biological processes and, in particular, in the DNA damage response (DDR). The most studied members, PARP1, PARP2 and PARP3, act as sensors of DNA damages, in order to activate different intracellular repair pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Padella, Antonella, Ghelli Luserna Di Rorà, Andrea, Marconi, Giovanni, Ghetti, Martina, Martinelli, Giovanni, Simonetti, Giorgia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783444/ https://www.ncbi.nlm.nih.gov/pubmed/35065680 http://dx.doi.org/10.1186/s13045-022-01228-0

Ejemplares similares

The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2019)

Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway
por: Padella, Antonella, et al.
Publicado: (2021)

Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2023)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2020)

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2021)

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
por: Bruno, Samantha, et al.
Publicado: (2022)

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
por: Fontana, Maria Chiara, et al.
Publicado: (2021)

The cell cycle checkpoint inhibitors in the treatment of leukemias
por: Ghelli Luserna di Rora’, A., et al.
Publicado: (2017)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
por: Giudice, Valentina, et al.
Publicado: (2020)

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations
por: Simonetti, Giorgia, et al.
Publicado: (2021)

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2019)

Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2019)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
por: Ferrari, Anna, et al.
Publicado: (2023)

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia
por: Padella, Antonella, et al.
Publicado: (2019)

Chromothripsis in Acute Myeloid Leukemia: biological features and impact on survival
por: Fontana, Maria Chiara, et al.
Publicado: (2017)

Chromothripsis in acute myeloid leukemia: biological features and impact on survival
por: Fontana, Maria Chiara, et al.
Publicado: (2018)

Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents
por: Simonetti, Giorgia, et al.
Publicado: (2021)

Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients
por: De Matteis, Serena, et al.
Publicado: (2018)

Aneuploidy: Cancer strength or vulnerability?
por: Simonetti, Giorgia, et al.
Publicado: (2018)

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
por: Trino, Stefania, et al.
Publicado: (2016)

Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia
por: Simonetti, Giorgia, et al.
Publicado: (2021)

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

An (1)H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia
por: Cerchione, Claudio, et al.
Publicado: (2020)

Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions
por: Beeharry, Neil, et al.
Publicado: (2015)

Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial
por: Cerchione, Claudio, et al.
Publicado: (2020)

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
por: Martino, Massimo, et al.
Publicado: (2021)

Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin
por: Ghetti, Martina, et al.
Publicado: (2020)

P451: GENE FUSIONS AND OTHER GENOMIC EVENTS UNDERLIE VENETOCLAX AND HYPOMETHYLATING AGENT RESISTANCE AND PROVIDE NEW TARGETS IN ACUTE MYELOID LEUKEMIA.
por: Ferrari, Anna, et al.
Publicado: (2023)

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2018)

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia
por: Iacobucci, Ilaria, et al.
Publicado: (2015)

Germline CSF3R Variant in Chronic Myelomonocytic Leukemia: Linking Genetic Predisposition to Uncommon Hemorrhagic Symptoms
por: Bochicchio, Maria Teresa, et al.
Publicado: (2023)

Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease
por: Traversa, Debora, et al.
Publicado: (2021)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
por: Caracciolo, Daniele, et al.
Publicado: (2021)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

PARP inhibitor re-sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
por: Wu, Jie, et al.
Publicado: (2019)

PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF- кB pathway activity and DNA damage response induced by Idarubicin : PARP-1 inhibitors attenuate DNA damage response
por: Ke, Bo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8pv0srck2devjq68p7b5g1j2p0